drugset
drugset / Trial / NCT00276380

A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

NCT00276380 ↗

Phase 3 Completed 204 enrolled Ipsen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.

Timeline

Start
2003-02
Primary completion
2009-03
Completion
2009-03

Outcome

Missed primary endpoint

registry NUMBER EGb761®: 59.8 percentage of participants NUMBER Placebo: 64.7 percentage of participants analysis (other test); EGb761® vs Placebo; p = 0.52 NCT00276380 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ginkgo Biloba Extract Traditional medicine (herbal / TCM) 240 mg Oral
Background Aspirin Small molecule 325 mg —

Indications

ischemic stroke